PRINCETON, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANIP) today announced results from the NEW DAY clinical trial of ILUVIEN® (fluocinolone acetonide intravitreal implant), 0 ...
ANI Pharmaceuticals has disclosed the outcomes of its randomised NEW DAY trial, assessing Iluvien 0.19mg, in people with diabetic macular oedema (DME). The multicenter, prospective, masked, ...
ANI Pharmaceuticals announced the results of the NEW DAY clinical trial for ILUVIEN® (fluocinolone acetonide) in diabetic macular edema (DME) patients during the ASRS Annual Scientific Meeting. The ...
Marbury Creative Group and Alimera Sciences are aiming to get diabetic macular edema (DME) treatment Iluvien on patients’ radars with the See Less to See More campaign. The nine-month effort, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results